Michael Hill
University Health Network
39 Papers
433 Citations
Michael Hill is an academic researcher from University Health Network. The author has contributed to research in topics: Dyskinesia & Levodopa. The author has an hindex of 19, co-authored 39 publications. Previous affiliations of Michael Hill include University of Manchester.
Chat about Author
Papers
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
TL;DR: Findings indicate a link between endocannabinoid signaling in the globus pallidus and symptoms of Parkinson's disease in the reserpine‐treated rat, and suggest that modulation of the endoc cannabinoidoid signaling system might prove useful in treating this or other basal ganglia‐related movement disorders.
347
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
Mario van der Stelt,Susan H. Fox,Michael Hill,Alan R. Crossman,Stefania Petrosino,Vincenzo Di Marzo,Jonathan M. Brotchie +6 more
TL;DR: It is shown that signaling by endocannabinoids contributes to the pathophysiology of parkinsonism and LID in MPTP‐lesioned, non‐human primate models of Parkinson's disease and the level of anandamide and 2‐arachidonyl glycerol throughout the basal ganglia is determined.
212
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
Joanne E. Nash,Susan H. Fox,Brian Henry,Michael Hill,David Peggs,Steve McGuire,Yannick P. Maneuf,C. J. Hille,Jonathan M. Brotchie,Alan R. Crossman +9 more
TL;DR: The data support the proposal that NR2B-selective NMDA receptor antagonists have potential as a nondopaminergic monotherapy for the treatment of parkinsonian symptoms when given de novo.
127
Antiparkinsonian Actions of Blockade of NR2B-Containing NMDA Receptors in the Reserpine-Treated Rat
TL;DR: This study demonstrates that selective blockade of NR2B-containing NMDA receptors with the polyamine antagonists ifenprodil and eliprodil causes a significant increase in locomotor activity in the reserpine-treated rat model of Parkinson's disease, and proposes that NR2 B-selective NMDA receptor antagonists may prove useful in the treatment of Parkinson's disease.
89
Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials
TL;DR: This work argues for further preclinical validation of the 12 candidate pharmacological agents with putative neuroprotective properties selected as potential candidates for upcoming clinical trials, due to a lack of published data.
84